Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use

Young Dae Kim, Jung Hwan Lee, Yo Han Jung, Hye Yeon Choi, Chung Mo Nam, Jae Hoon Yang, Han Jin Cho, Hyo Suk Nam, Kyung Yul Lee, Ji Hoe Heo

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

Background: Hemorrhage is a major complication of thrombolytic treatment. Concerns have been raised about the risk of hemorrhage in patients having received warfarin. Therefore, different indications for thrombolytic treatment are in use for stroke patients on warfarin. However, it remains uncertain whether the prior warfarin use actually increases their risk of bleeding in patients treated with thrombolysis. Methods: This study included 179 consecutive patients who had high-risk cardioembolic sources and received thrombolytic treatment. Patients were treated with intravenous thrombolytic agents, or underwent intraarterial thrombolysis if their international normalized ratio (INR) was ≤ 1.7. We compared the frequency of bleeding complications between patients with prior warfarin use and those without. We also investigated whether there were differences in functional outcome and recanalization rates between them. Results: A prior warfarin use was present in 28 patients (15.6%). Although INR levels were higher in the prior warfarin group, the frequency of bleeding complications was not different between patients who received prior warfarin and those who did not. No differences were observed in patients with or without prior warfarin use, for successful recanalization rate (Thrombolysis in Myocardial Infarction grade 2 or 3), mortality, or modified Rankin score (≤ 2) at 3 months. Conclusions: Thrombolytic therapy for patients who previously received warfarin and had an INR ≤ 1.7 did not affect bleeding risk, clinical outcome, or recanalization rate. Our data suggest that patients with a history of prior warfarin use may be safely treated with thrombolytic agents when their INR levels are low.

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalJournal of the Neurological Sciences
Volume298
Issue number1-2
DOIs
Publication statusPublished - 2010 Nov 15

Bibliographical note

Funding Information:
This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, & Family Affairs, Republic of Korea ( A085136 , A091273 ), and by a faculty research grant of Yonsei University College of Medicine for 2009 ( 6-2009-0111 ).

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use'. Together they form a unique fingerprint.

Cite this